Compare Dropbox Inc (DBX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Sana Biotechnology Inc — how do they compare? Dropbox Inc trades at $33.64 (market cap $7.41B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Dropbox Inc is far larger — about 6.6× Sana Biotechnology Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| DBX | SANA | |
|---|---|---|
Market Cap | $7.41B | $1.13B |
Sector | Technology | Health |
52-Week High | $35.00 | $5.92 |
52-Week Low | $22.06 | $2.68 |
Enterprise Value | $10.27B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $33.79, down 2.31% today, but maintains a bullish technical trend with consistent earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.75, exceeding expectations, and raised its full-year outlook. Strong profitability margins and positive cash flow trends support fundamentals, though negative shareholder equity and high debt levels present financial risks. Analyst sentiment is mixed with a balanced buy/hold/sell distribution.
The outlook for DBX is cautiously optimistic, driven by earnings momentum and AI expansion, but investors face risks from leveraged balance sheets and competitive pressures. Upside potential hinges on sustained core business growth, while downside risks include debt servicing and market volatility. The stock offers growth appeal but requires monitoring of financial health.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
